Champions Oncology (CSBR) EBT Margin (2010 - 2026)
Champions Oncology (CSBR) recorded quarterly EBT Margin of 1.43% in Q1 2026, down 184.39% quarter-over-quarter from 1.7% in Q4 2025, and down 2795.0% on a YoY basis from 0.05% in Q1 2025.
Champions Oncology (CSBR) EBT Margin (2010 - 2026) Analysis & Trends
Champions Oncology's EBT Margin history runs 17 years deep, the most recent figure standing at 1.43% for Q1 2026.
- In Q1 2026, EBT Margin fell 2795.0% year-over-year to 1.43%; the TTM figure through Jan 2026 stood at 4.14% (down 1506.0% YoY), while the FY2025 annual figure was 8.12%, up 2269.0% from the prior year.
- EBT Margin was 1.43% for Q1 2026 at Champions Oncology, down from 1.7% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 26.52% in Q1 2025 to a low of 20.96% in Q1 2024.
- Historically, EBT Margin has averaged 4.41% across 5 years, with a median of 2.2% in 2022.
- The sharpest annual moves came in 2025 and 2026: EBT Margin jumped 4747 bps in 2025, then plunged 2795 bps in 2026.
- A 5-year view of EBT Margin shows it stood at 0.01% in 2022, then slumped by 127001 bps to 17.8% in 2023, then surged by 131 bps to 5.48% in 2024, then tumbled by 69 bps to 1.7% in 2025, then sank by 184 bps to 1.43% in 2026.
- The last three EBT Margin figures came in at 1.43% (Q1 2026), 1.7% (Q4 2025), and 3.23% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -1.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -1.43% |
| Oct 31, 2025 | 1.70% |
| Jul 31, 2025 | -3.23% |
| Apr 30, 2025 | -15.90% |
| Jan 31, 2025 | 26.52% |
| Oct 31, 2024 | 5.48% |
| Jul 31, 2024 | 9.49% |
| Apr 30, 2024 | -1.36% |
| Jan 31, 2024 | -20.96% |
| Oct 31, 2023 | -17.80% |
| Jul 31, 2023 | -20.21% |
| Apr 30, 2023 | -19.44% |
| Jan 31, 2023 | -18.96% |
| Oct 31, 2022 | -0.01% |
| Jul 31, 2022 | -2.20% |
| Apr 30, 2022 | -2.69% |
| Jan 31, 2022 | 6.05% |
| Oct 31, 2021 | 2.45% |
| Jul 31, 2021 | -1.40% |
| Apr 30, 2021 | -6.07% |